Market Overview

Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm

Share:
Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm

Can-Fite BioPharma (NYSE: CANF) 6-K shows the company filed an appeal with the Supreme Court of Israel of a decision related to the convening of a special shareholder meeting to replace directors.

On June 13, Can-Fite BioPharma filed a lawsuit against Capital Point Ltd; its co-CEOs, Shay Itzhak Lior and Yossi Tamar; its chairman, Dr. Shuki Gleitman; and its major shareholders, Shir Roichman and Yehuda Kahane, in the District Court of Tel Aviv.

The lawsuit alleges that Capital Point engaged in improper conduct by unlawfully requesting that the company convene a shareholder meeting to replace its directors. Can-Fite BioPharma is suing for damages of NIS 40 million (approximately $11.1 million). 

A related action Can-Fite BioPharma initiated against Capital Point in the District Court of Tel Aviv is still pending.

Can-Fite BioPharma shares were trading flat at $2.91 at the time of publication Wednesday. The stock has a 52-week high of $25.95 and a 52-week low of $2.66.

Related Links:

Amneal Announces Restructuring Plan, Cuts Guidance

Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio

The Supreme Court of Israel. Photo by israeltourism/Wikimedia

Posted-In: Biotech News Legal General Best of Benzinga

 

Related Articles (CANF)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

10 Biggest Price Target Changes For Wednesday

Moleculin Rallies On Patent Applications That Could Give Cancer Drug 20 Years of Protection